tradingkey.logo
tradingkey.logo
Search

Novo Nordisk A/S

NVO
Add to Watchlist
47.410USD
+1.530+3.33%
Close 06/23, 16:00ETQuotes delayed by 15 min
158.87BMarket Cap
11.09P/E TTM

TradingKey Stock Score of Novo Nordisk A/S

Currency: USD Updated: 2026-06-23

Key Insights

Novo Nordisk A/S's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 71 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 49.61.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Novo Nordisk A/S's Score

Industry at a Glance

Industry Ranking
71 / 157
Overall Ranking
154 / 4573
Industry
Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Negative-

Novo Nordisk A/S Highlights

StrengthsRisks

Novo Nordisk A/S is a Danish multinational pharmaceutical firm headquartered in Bagsværd, with manufacturing facilities across nine countries and affiliates or offices in five others. The company is predominantly controlled by its majority shareholder, Novo Holdings A/S, which owns approximately 28.1% of its shares and a majority of its voting rights.

Novo Nordisk specializes in the production and marketing of pharmaceutical products and services, focusing primarily on diabetes care medications and devices. Among its key products is semaglutide, utilized for diabetes treatment under the brand names Ozempic and Rybelsus, as well as for obesity treatment under the brand name Wegovy. The company also engages in hemostasis management, growth hormone therapy, and hormone replacement therapy, producing numerous drugs under various brand names such as Levemir, Tresiba, NovoLog, Novolin R, NovoSeven, NovoEight, and Victoza.

Employing over 48,000 individuals worldwide, Novo Nordisk distributes its products in 168 countries. The corporation was formed in 1989 from a merger of two Danish companies with origins tracing back to the 1920s. The Novo Nordisk logo features the Apis bull, a sacred animal from ancient Egypt, represented by the hieroglyph 𓃒. Novo Nordisk is also a full member of the European Federation of Pharmaceutical Industries and Associations.

Recognized for its workplace culture, the company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, later ranking 72nd in 2014 and 73rd in 2017. In January 2012, Novo Nordisk was acclaimed as the most sustainable company globally by Corporate Knights, while its spin-off, Novozymes, secured the fourth position. The company is a leader in the FTSE4Good Index and stands as the only European firm in the top ten list. As the largest pharmaceutical company in Denmark, Novo Nordisk's market capitalization surpassed the GDP of Denmark's domestic economy in 2023, making it the highest valued company in Europe, with net sales reaching US$42.121 billion in 2024.

High Growth
The company's revenue has grown steadily over the past 3 years, averaging 38.54% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 46.70B.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 50.19%.
Stable Dividend
The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 50.19%.
Undervalued
The company’s latest PE is 11.09, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 332.82M shares, decreasing 0.81% quarter-over-quarter.
Held by Sarah Ketterer
Star Investor Sarah Ketterer holds 7.39M shares of this stock.

Analyst Rating

Based on 14 analysts
Hold
Current Rating
49.612
Target Price
+8.14%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

FAQs

How does TradingKey generate the Stock Score of Novo Nordisk A/S?

The TradingKey Stock Score provides a comprehensive assessment of Novo Nordisk A/S based on 34 indicators derived from over 100 underlying data points.
These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Novo Nordisk A/S’s performance and outlook.

How do we generate the financial health score of Novo Nordisk A/S?

To generate the financial health score of Novo Nordisk A/S, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns.
By integrating these comprehensive data, the financial health score not only reflects Novo Nordisk A/S's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Novo Nordisk A/S.

How do we generate the company valuation score of Novo Nordisk A/S?

To generate the company valuation score of Novo Nordisk A/S, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Novo Nordisk A/S’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value.
By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Novo Nordisk A/S’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Novo Nordisk A/S.

How do we generate the earnings forecast score of Novo Nordisk A/S?

To calculate the earnings forecast score of Novo Nordisk A/S, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:
Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.
Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.
By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.
Comparing these indicators against peers provides context for the stock’s performance and helps anchor more realistic expectations.
These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Novo Nordisk A/S’s future.

How do we generate the price momentum score of Novo Nordisk A/S?

When generating the price momentum score for Novo Nordisk A/S, we examine momentum indicators including support and resistance levels as well as volume metrics.
Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.
This comprehensive approach can reflect market sentiment and enable rational forecasts of Novo Nordisk A/S’s prices. A higher score indicates a more stable short-term price trend for Novo Nordisk A/S.

How do we generate the institutional confidence score of Novo Nordisk A/S?

To generate the institutional confidence score of Novo Nordisk A/S, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Novo Nordisk A/S’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Novo Nordisk A/S.

How do we generate the risk management score of Novo Nordisk A/S?

To assess the risk management score of Novo Nordisk A/S, we examine multiple key indicators related to returns, risk, volatility, and liquidity.
The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.
These indicators together provide a multi-dimensional understanding of Novo Nordisk A/S’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Novo Nordisk A/S.
KeyAI